Welcome to our dedicated page for Hemostemix news (Ticker: HMTXF), a resource for investors and traders seeking the latest updates and insights on Hemostemix stock.
Hemostemix Inc. (HMTXF) generates news that spans biotechnology, clinical development, and commercialization of autologous stem cell therapy for ischemic disease. The company’s updates frequently center on its VesCell (ACP-01) platform, a patient-derived blood-based stem cell therapy that Hemostemix reports has been studied in multiple clinical trials for peripheral arterial disease, chronic limb threatening ischemia, cardiomyopathies, congestive heart failure, angina, total body ischemia, and vascular dementia.
Investors following HMTXF news can expect regular announcements on clinical milestones, regulatory interactions, and physician-led initiatives. Hemostemix has reported the completion of a Phase II clinical trial in chronic limb threatening ischemia, publication of results in peer-reviewed journals, and presentations of long-term outcomes such as limb preservation, wound healing, and mortality data in severe ischemic patient populations. News items also describe plans for a basket protocol Phase I trial in ischemia-related conditions and a scheduled FDA Pre-IND meeting to review the company’s proposed trial design and regulatory pathway.
Corporate developments are another recurring theme in Hemostemix’s news flow. The company issues releases on non-brokered private placements, stock option grants, and capital raises intended to fund regulatory, clinical, and commercialization activities for ACP-01. It also reports on strategic moves such as a clinic roll-up strategy, including letters of intent to acquire cardiology practices that have experience treating patients with ACP-01, as well as the build-out of patient care and clinical operations roles.
Sector-specific coverage includes Hemostemix’s participation in conferences focused on wound healing, diabetic limb salvage, and regenerative medicine, where the company highlights its CLTI and cardiovascular data. For readers tracking HMTXF, this news page offers a consolidated view of scientific, regulatory, financial, and operational updates related to Hemostemix’s autologous stem cell therapy platform.
Hemostemix (TSXV: HEM) (OTC: HMTXF) announces growing traction in its social media awareness campaign across multiple platforms, promoting its trademarked "Your Fountain of Youth"™ regenerative medicine treatments. The campaign shares patient success stories and educates about innovative treatments for no-option cardiovascular diseases.
The company's ACP-01 treatment, derived from patients' blood and cultured in their serum, has shown significant results:
- In dilated cardiomyopathy patients, cardiac function improved by up to 47.1% after one treatment
- For Chronic Limb Threatening Ischemia (CLTI), 83% of patients followed for up to 4.5 years experienced healing of ulcers and pain resolution
- Ulcer size decreased significantly from 1.46 cm² to 0.48 mm² within three months in phase II trials
Hemostemix (TSXV: HEM) (OTC: HMTXF) has launched a comprehensive social media campaign across Instagram, Facebook, LinkedIn, YouTube, and X to showcase patient success stories and educate about their regenerative medicine treatments. The company's flagship treatment, ACP-01, derived from patients' own blood and cultured in their serum, has demonstrated significant clinical results:
In dilated cardiomyopathy patients, cardiac function improved by up to 47.1% after one treatment, with notable improvements in severe cases. For Chronic Limb Threatening Ischemia (CLTI) patients, 83% experienced healing of ulcers and resolution of ischemic rest pain in follow-ups up to 4.5 years. Ulcer size decreased significantly from 1.46 cm² to 0.48 mm² within three months.
Hemostemix has announced an update to its second closing, adding a $50,000 subscription to reach total gross proceeds of $2,725,981.77 through the issuance of 54,519,635 Units. The company paid finder fees of approximately $28,820.64 and issued 576,413 finder's options exercisable at $0.05 per Common Share within 24 months.
The offering includes participation from company directors, constituting a related party transaction under MI 61-101. The company is exempt from formal valuation and minority shareholder approval requirements as the transaction value does not exceed 25% of market capitalization. All securities issued will have a four-month hold period from the closing date.
Hemostemix has completed its second and final tranche of private placement, raising $833,258 through the issuance of 16,665,160 Units at $0.05 per Unit. The combined offerings totaled $2,675,981.77 with 53,519,635 Units issued. Each Unit includes one common share and one warrant exercisable at $0.12 per share for 24 months. The proceeds will fund the company's stem cell therapeutics platform, initiate ACP sales, and cover operational expenses. The company paid approximately $24,820.64 in finder fees and issued 496,413 finder's options.
Hemostemix announces the launch of a social media campaign to promote and sell ACP-01 treatments under special access programs for various cardiovascular conditions. ACP-01, proven safe in 498 treatments across six clinical trials and one retrospective study with 318 subjects, has shown significant results. Notable outcomes include up to 47.1% improvement in cardiac function for dilated cardiomyopathy patients and 83% healing rate in CLTI patients. Recent CIHI data reveals concerning statistics about diabetes-related amputations, including 7,720 hospitalizations for lower limb amputations, with average hospitalization costs of $47,000 and annual costs reaching $750 Million.
Hemostemix has closed the first tranche of its private placement, raising $1.8 million through the issuance of 36.8 million Units at $0.05 per Unit. Each Unit includes one common share and one warrant exercisable at $0.12 for 24 months. The company paid finder fees of $88,660 and issued 1.7 million finder's options. Additionally, the company granted 3.7 million stock options to directors, officers, employees, and consultants at $0.10 per share, expiring October 31, 2029. The company will also issue 4.1 million shares at $0.10 per share to satisfy $408,547 in convertible debenture interest.
Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) (FSE: 2VF0) has announced a private placement to raise up to $4,000,000 through the sale of Common Shares and Units at $0.05 each. Each Unit comprises one Common Share and one Warrant, allowing the holder to acquire an additional Common Share at $0.12 within 24 months of closing. The Warrants include an accelerated expiry provision if the stock price reaches or exceeds $0.15 for 10 consecutive trading days after four months from closing.
The company may involve directors in the private placement, which would be considered a 'related party transaction' under MI 61-101. Hemostemix is utilizing exemptions from formal valuation and minority shareholder approval requirements. All securities issued will be subject to a four-month hold period from the closing date.
Hemostemix Inc. (TSXV: HEM) (OTC Pink: HMTXF) has signed a funded Manufacturing Services Agreement with CytoImmune Therapeutics to restart production of ACP-01, a stem cell therapy for cardiovascular diseases. The agreement is funded by issuing 30,140,000 common shares of Hemostemix at $0.05 each to CytoImmune. It covers the production of the first 22 ACP-01 therapies, which Hemostemix will sell for $1,100,000 ($50,000 each).
The companies aim to produce the first ACP-01 therapy by Q1 2025. Hemostemix expects to generate substantial cash flow from treating 480 no-option patients annually. The company is also closing a private placement of up to $2,000,000 from the sale of 40 Million Units at $0.05 each, with proceeds used for sales, marketing, and working capital.
Hemostemix announced it has been granted the trademark 'Your Fountain of Youth' by the Swiss Trademark Office, a significant milestone for the company's intellectual property portfolio.
CEO Thomas Smeenk highlighted the positive results from ACP-01, their cardiovascular treatment, with a 27% improvement in LVEF% and notable reductions in ulcer size, amputation, and mortality rates in clinical trials.
Additionally, Hemostemix will make a 2023 interest payment of $226,688.25 to debenture holders via 2,229,616 shares at $0.101671 per share, subject to regulatory approval and a four-month hold period under Canadian securities laws.
Hemostemix announced a strategic partnership with CytoImmune Therapeutics to re-establish ACP-01 production at CytoImmune's facility in Puerto Rico. The company secured $1,800,000 in financing commitments through a private placement at $0.05 per unit. CytoImmune will subscribe for $1,370,000 worth of these units. The partnership aims to scale production of ACP-01, a treatment for chronic limb-threatening ischemia (CLTI), potentially reaching sales of $2 million per month by 2025. Hemostemix's phase II clinical trial showed promising results, with 83% of patients experiencing ulcer healing and pain cessation. The proceeds of the financing will be used for initial batch processing and working capital.